Levicept presents new LEVI-04 data at EULAR

Biotech firm shares phase 2 findings on novel osteoarthritis treatmen

Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025). The first-in-class biologic, designed as a non-addictive pain treatment, showed significant and clinically meaningful improvements in knee osteoarthritis patients, including enhanced physical function beyond pain relief.

LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein that provides analgesia by inhibiting NT-3 activity, modulating excess neurotrophin levels associated with osteoarthritis. The phase 2 study, a randomised, double-blind trial involving 518 participants, previously confirmed significant analgesia across all doses.

Further analysis revealed rapid pain relief within three days and an improvement in function that exceeded expectations based on pain reduction alone. The data were presented by Professor Philip Conaghan, Director of NIHR Leeds Biomedical Research Centre, during an oral session on June 14.

Professor Philip Conaghan said: “These new data we are presenting at EULAR further support our belief that LEVI-04 has the potential to offer a vital new treatment option to millions of patients in need.”

Levicept also showcased results from a novel evoked pain model that demonstrated LEVI-04’s effectiveness compared to placebo. The presentation highlighted the drug’s promising role in improving mobility and overall patient outcomes.

Eliot Forster, CEO of Levicept said: “We continue to see significant interest in the results from our phase 2 study at international medical conferences, underlining their importance.”

Levicept is advancing its strategy for LEVI-04’s further development, aiming to bring this innovative treatment to the patients who need it most.